G Protein-Dependent Activation of the PKA-Erk1/2 Pathway by the Striatal Dopamine D1/D3 Receptor Heteromer Involves Beta-Arrestin and the Tyrosine Phosphatase Shp-2
Biomolecules · 2023
DOI: 10.3390/biom13030473 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Federica Bono und 7 weiteren Autor:innen. Beteiligte Einrichtung: Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Viale Europa 11, 25123 Brescia, Italy. Hauptthemen laut MEDLINE: Dopamine, Levodopa. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Michael J. Fox Foundation for Parkinson Research, New York, USA, Fondazione CARIPLO (2012–2014), University of Brescia Italy.
Abstract (Originalsprache)
The heteromer composed of dopamine D1 and D3 receptors (D1R–D3R) has been defined as a structure able to trigger Erk1/2 and Akt signaling in a G protein-independent, beta-arrestin 1-dependent way that is physiologically expressed in the ventral striatum and is likely involved in the control of locomotor activity. Indeed, abnormal levels of D1R-D3R heteromer in the dorsal striatum have been correlated with the development of L-DOPA-induced dyskinesia (LID) in Parkinson’s disease patients, a motor complication associated with striatal D1R signaling, thus requiring Gs protein and PKA activity to activate Erk1/2. Therefore, to clarify the role of the D1R/D3R heteromer in LID, we investigated the signaling pathway induced by the heteromer using transfected cells and primary mouse striatal neurons. Collectively, we found that in both the cell models, D1R/D3R heteromer-induced activation of Erk1/2 exclusively required the D1R molecular effectors, such as Gs protein and PKA, with the contribution of the phosphatase Shp-2 and beta-arrestins, indicating that heterodimerization with the D3R abolishes the specific D3R-mediated signaling but strongly allows D1R signals. Therefore, while in physiological conditions the D1R/D3R heteromer could represent a mechanism that strengthens the D1R activity, its pathological expression may contribute to the abnormal PKA-Shp-2-Erk1/2 pathway connected with LID.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Viale Europa 11, 25123 Brescia, Italy.
- Seattle Children's Research Institute, 1920 Terry Ave., Seattle, WA 98101, USA.
ORCID-Profile: Federica Bono, Veronica Mutti, Francesca Longhena, Chiara Fiorentini
Förderung
- The Michael J. Fox Foundation for Parkinson Research, New York, USA
- Fondazione CARIPLO (2012–2014)
- University of Brescia Italy
Zitieren
APA
Bono, F., Tomasoni, Z., Mutti, V., Sbrini, G., Kumar, R., Longhena, F., Fiorentini, C., & Missale, C. (2023). G Protein-Dependent Activation of the PKA-Erk1/2 Pathway by the Striatal Dopamine D1/D3 Receptor Heteromer Involves Beta-Arrestin and the Tyrosine Phosphatase Shp-2. Biomolecules. https://doi.org/10.3390/biom13030473
Vancouver
Bono F, Tomasoni Z, Mutti V, Sbrini G, Kumar R, Longhena F, et al. G Protein-Dependent Activation of the PKA-Erk1/2 Pathway by the Striatal Dopamine D1/D3 Receptor Heteromer Involves Beta-Arrestin and the Tyrosine Phosphatase Shp-2. Biomolecules. 2023. doi:10.3390/biom13030473
BibTeX
@article{Bono2023,
author = {Bono, Federica and Tomasoni, Zaira and Mutti, Veronica and Sbrini, Giulia and Kumar, Rajesh and Longhena, Francesca and Fiorentini, Chiara and Missale, Cristina},
title = {G Protein-Dependent Activation of the PKA-Erk1/2 Pathway by the Striatal Dopamine D1/D3 Receptor Heteromer Involves Beta-Arrestin and the Tyrosine Phosphatase Shp-2},
journal = {Biomolecules},
year = {2023},
doi = {10.3390/biom13030473}
}
EUVIMED